Michiel is a leader in Deloitte’s Strategy & Transactions Life Sciences practice, focused on growth strategy, M&A and strategic alliances topics. He helps his clients pursue inorganic growth opportunities by defining M&A strategies, executing operational & commercial diligence, and managing integration & divestiture execution. He plays at the intersection of pharmaceuticals, med tech, and technology with deals ranging from $100M-$40B in size.
Market: Deloitte United States